je.st
news
Home
› Oligomerix Awarded A Grant For Its Alzheimer's Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health
Oligomerix Awarded A Grant For Its Alzheimer's Drug Discovery Program Targeting Tau Oligomers From The National Institutes Of Health
2016-05-03 02:45:01| drugdiscoveryonline News Articles
Oligomerix, Inc., a privately held company targeting tau oligomers for developing disease modifying therapeutics for Alzheimer’s disease (AD) and related neurodegenerative disorders, announced recently the receipt of an award for a Direct-to-Phase-II Small Business Innovation Research (SBIR) grant for a two year program for a total of $1.5 M from the National Institutes of Health (NIH), National Institute on Aging (NIA)
Tags: of
health
program
national
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||